Skip to main navigation

Investor Relations

March 03, 2021
Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal “Gastroenterology"
March 01, 2021
Abivax appoints Dr Sophie Biguenet as Chief Medical Officer
January 05, 2021
Abivax publishes review in Drug Discovery Today on mechanism of action and transformative potential of ABX464 as therapy for inflammatory diseases
December 22, 2020
Abivax’s Covid-19 phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government’s clinical trial council
December 21, 2020
Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of major clinical milestones